Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials

Guo, Boda; Chen, Xin; Wang, Miao; Hou, Huimin; Zhang, Zhipeng; Liu, Ming

doi:10.12659/msm.923179

Cited by 8 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmaceuticals 2023, 16, x FOR PEER REVIEW 7 of 61 evaluated and was confirmed to often outperform either type of monotherapy [66][67][68][69][70]. Interestingly, a very recent meta-analysis of randomized clinical trials demonstrated that tadalafil could be superior to tamsulosin in treating LUTS/BPH when associated with ED [71].…”

Section: Cancermentioning

confidence: 99%

“…The combined administration of sildenafil, tadalafil or vardenafil with the α 1 -adrenoceptor antagonists alfuzosin or tamsulosin for the treatment of LUTS/BPH has also been evaluated and was confirmed to often outperform either type of monotherapy [ 66 , 67 , 68 , 69 , 70 ]. Interestingly, a very recent meta-analysis of randomized clinical trials demonstrated that tadalafil could be superior to tamsulosin in treating LUTS/BPH when associated with ED [ 71 ].…”

Section: Pde5 As a Drug Target For Disease Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

ElHady,

El-Gamil,

Abdel-Halim

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes. Beyond their well-known efficacy in treating male erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), a plethora of studies have unveiled their significance in the treatment of a myriad of other diseases, including cognitive functions, heart failure, multiple drug resistance in cancer therapy, immune diseases, systemic sclerosis and others. This comprehensive review aims to provide an updated assessment of the crucial role played by PDE5 inhibitors (PDE5-Is) as disease-modifying agents taking their limiting side effects into consideration. From a medicinal chemistry and drug discovery perspective, the published PDE5-Is over the last 10 years and their binding characteristics are systemically discussed, and advancement in properties is exposed. A persistent challenge encountered with these agents lies in their limited isozyme selectivity; considering this obstacle, this review also highlights the breakthrough development of the recently reported PDE5 allosteric inhibitors, which exhibit an unparalleled level of selectivity that was rarely achievable by competitive inhibitors. The implications and potential impact of these novel allosteric inhibitors are meticulously explored. Additionally, the concept of multi-targeted ligands is critically evaluated in relation to PDE5-Is by inspecting the broader spectrum of their molecular interactions and effects. The objective of this review is to provide insight into the design of potent, selective PDE5-Is and an overview of their biological function, limitations, challenges, therapeutic potentials, undergoing clinical trials, future prospects and emerging uses, thus guiding upcoming endeavors in both academia and industry within this domain.

show abstract

Section: Cancermentioning

confidence: 99%

Section: Pde5 As a Drug Target For Disease Treatmentmentioning

confidence: 99%

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

ElHady,

El-Gamil,

Abdel-Halim

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…A 2020 meta-analysis of seven RCTs (N=1,601) evaluated the effect of tadalafil compared with tamsulosin in the treatment of LUTS from BPH. 2 The trials included adult male patients treated with tadalafil 5 mg or tamsulosin 0.2 or 0.4 mg once daily over 12 weeks. The primary outcomes were similar to the previous meta-analysis, with the addition of the International Index of Erectile Function (IIEF).…”

mentioning

confidence: 99%

Is tadalafil effective in treating lower urinary tract symptoms in males with benign prostatic hyperplasia?

Rohrbough,

Colgan,

Gasser

2023

EBPR

View full text Add to dashboard Cite

Pharmakologische Therapie

Lusuardi¹

2022

Benignes Prostatasyndrom

View full text Add to dashboard Cite

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials

Cited by 8 publications

References 30 publications

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

Is tadalafil effective in treating lower urinary tract symptoms in males with benign prostatic hyperplasia?

Pharmakologische Therapie

Contact Info

Product

Resources

About